title: RenaGel (Geltex Pharmaceuticals Inc).
abstract: RenaGel, developed by GelTex, is a polymer that binds and removes dietary phosphate from the intestinal tract without being absorbed into the bloodstream. A US NDA for control of hyperphosphatemia in patients with chronic renal failure was filed in October 1997 and accepted for review in January 1998. Marketing approval was granted in November 1998. The compound has also achieved part B status in Europe. Merrill Lynch predict RenaGel will achieve worldwide sales of $220 million by 2001.
authors.affiliation: Schwerpunkt Nephrologie Medische Klinikum, Klinikum Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany. Kai.vonAppen@lrz.uni-muenchen.de
authors.forename: K
authors.initials: K
authors.lastname: von Appen